Pulmonary lymphoma, a rare form of cancer originating in the lungs, involves the proliferation of malignant lymphocytes. Cancer research has been pivotal in enhancing our understanding of this disease, particularly its subtypes such as primary pulmonary lymphoma and secondary involvement of the lungs by systemic lymphoma. Advances in molecular biology and immunohistochemistry have improved diagnostic accuracy, enabling differentiation from other lung malignancies and infections. Research has also explored targeted therapies, including monoclonal antibodies and kinase inhibitors, offering new hope for treatment beyond conventional chemotherapy and radiotherapy. Ongoing clinical trials and genomic studies are crucial, aiming to uncover specific genetic mutations and immune profiles that can be targeted to personalize treatment strategies and improve patient outcomes.



Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Nanomedicine in over 45,000 patients and no cancer
Thomas Jay Webster, Brown University, United States